Exhibit 99.4
Dear [Valued Partner / INSERT CUSTOMARY GREETING],
This
morning, Morphic announced that it has entered into an agreement to be acquired by Eli Lilly and Company (Lilly), marking a new phase for our company and the potential for oral integrin medicines. You can read more about the announcement
in our joint press release <INSERT LINK>.
Morphic believes and has stated that the patient impact of
MORF-057 could be significantly enhanced by the partnership with a global medicines company. We are confident we have found that partner in Lilly, a globally recognized medicines company committed to improving
patient health. Our Board of Directors determined that proceeding with this transaction is the best path forward for Morphic. In addition to creating shareholder value, we believe that the transaction will deliver benefits for patients as
Lillys scale, resources, global footprint and approval track record will help advance MORF-057 and our integrin discovery platform beyond what we could as a standalone company.
Importantly, this announcement has no impact on the ongoing enrollment in our EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis or our continued progress on our GARNET Phase 2 study in Crohns disease. This work is continuing without disruption, and we remain committed to our mission of delivering a new
generation of integrin medicines to patients. We are grateful to the investigators and patients who have contributed to the success of MORF-057 thus far, and we eagerly anticipate the path forward for MORF-057 and other integrin medicines under Lillys stewardship.
We expect the transaction to be completed in the
third quarter of 2024, subject to customary closing conditions. Until then, we will continue to operate as an independent company, and it is business as usual. All contract terms remain in place, and we look forward to working with you like we
always have.
If you have any further questions, please dont hesitate to reach out to your normal company contact.
We value our relationship with you and appreciate your continued support as we move forward with Lilly.
Sincerely,
Cautionary Notice Regarding Forward-Looking
Statements
This communication contains forward-looking statements relating to the proposed acquisition of Morphic Holding, Inc., a
Delaware corporation (the Company), by Eli Lilly and Company, an Indiana corporation (Parent). Such forward-looking statements include, but are not limited to, the ability of the Company and Parent to complete
the transactions contemplated by the Agreement and Plan of Merger, dated July 7, 2024, between Parent, the Company and Rainier Acquisition Corporation, a Delaware corporation (Purchaser) and wholly-owned subsidiary of Parent
(the Merger Agreement), including the parties ability to satisfy the conditions to the consummation of the tender offer (the offer) contemplated thereby and the other conditions set forth in the Merger
Agreement, statements about the expected timetable for completing the transaction, the Companys and Parents beliefs and expectations and statements about the benefits sought to be achieved by Parents proposed acquisition of the
Company, the potential effects of the acquisition on both the Company and Parent, and the possibility of any termination of the Merger Agreement. In some cases, forward-looking statements may be identified by terminology such as believe,
may, will, should, predict, goal, strategy, potentially, estimate, continue, anticipate, intend, could,
would, project, plan, expect, seek and similar expressions and variations thereof. These words are intended to identify forward-looking statements. The Company has based these